NANO-X IMAGING LTD - Ordinary Shares (NNOX)

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) and certain officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 26-cv-07062, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nano-X securities between March 31, 2025 and April 17, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) investors concerning the Company’s possible violations of the federal securities laws.

LOS ANGELES, June 16, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX) securities during the period of March 31, 2025 through April 17, 2026, inclusive (“the Class Period”).

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nano-X (NNOX) To Contact Him Directly To Discuss Their Options

The Law Offices of Frank R. Cruz announces an investigation of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026. Nano-X describes itself as a company that “develops a commercial-grade tomographic imaging device with a digital X-ray source.”

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.

PETACH TIKVA, Israel, June 11, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2026, before market open on Thursday, June 25, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

Initial deployment is expected to include six Nanox.ARC systems under a capex model

Nano-X Imaging (NNOX) Q4 2025 Earnings Transcript

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifying. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) ( Profile ) is taking a distinctive approach: harnessing artificial intelligence (“AI”) and voice analysis to predict impairment from brief speech recordings. By treating the human voice as a window into underlying physiological and cognitive states, MindBio is focused on building a platform capable of detecting intoxication across a wide variety of substances in real time. This approach addresses a meaningful gap in existing detection technology and reflects a larger move toward AI-powered, noninvasive diagnostics with the potential to reshape how enforcement, employers and health systems identify and respond to impairment. MindBio is part of a broader group of companies working at the crossroads of health and AI, including Spectral AI Inc. (NASDAQ: MDAI), Nano-X Imaging Ltd. (NASDAQ: NNOX), NVIDIA Corporation (NASDAQ: NVDA) and…

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifying. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (profile) is taking a distinctive approach: harnessing artificial intelligence (AI) and voice analysis to predict impairment from brief speech recordings. By treating the human voice as a window into underlying physiological and cognitive states, MindBio is focused on building a platform capable of detecting intoxication across a wide variety of substances in real-time. This approach addresses a meaningful gap in existing detection technology and reflects a larger move toward AI-powered, noninvasive diagnostics with the potential to reshape how enforcement, employers and health systems identify and respond to impairment. MindBio is part of a broader group of companies working at the crossroads of health and AI, including Spectral AI Inc. (NASDAQ: MDAI), Nano-X Imaging Ltd. (NASDAQ: NNOX), NVIDIA Corporation (NASDAQ: NVDA) and Caris Life Sciences Inc. (NASDAQ: CAI).

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

Advances Nanox’s ongoing U.S. commercialization and deployment efforts

The law firm of Kirby McInerney LLP continues its investigation on behalf of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) for violations of the securities laws.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nano-X (NNOX) To Contact Him Directly To Discuss Their Options

Expands Nanox’s growing network of U.S. distribution partnerships